The Checkup by Singlecare
FEBRUARY 18, 2025
Jardiance (empagliflozin) is a brand-name prescription drug that has been FDA approved as a supplement to diet and exercise to improve blood sugar levels in people with Type 2 diabetes. It is also FDA-approved to treat chronic kidney disease (CKD) in those at risk of progression and reduce the risk of cardiovascular death in adults with either heart failure or Type 2 diabetes and cardiovascular disease.
STAT
FEBRUARY 18, 2025
Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the companies said Tuesday. For Biogen, acquiring international commercial rights to the Stoke drug bolsters its rare disease and neurology pipeline, and provides another product that could help it return to growth in the latter part of the decade.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The FDA Law Blog
FEBRUARY 18, 2025
By Richard A. Lewis, , Principal Regulatory Device and Biologics Expert The FDA is currently funded through March 1st, 2025. Come Monday March 3rd, if Congress does not pass a budget or continuing resolution, the FDA will enter a shutdown and shutter many offices and programs while Congress works out their inter-party squabbles on national priorities.
STAT
FEBRUARY 18, 2025
California officials were dealt a setback by a federal judge who ruled that a controversial law banning so-called pay-to-delay deals between pharmaceutical companies is, in part, unconstitutional and so cannot be enforced against agreements that had no link to the state. In his ruling , U.S. District Court Judge Troy Nunley determined that the state law, which was enacted in 2019, violated the Dormant Commerce Clause of the U.S.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The FDA Law Blog
FEBRUARY 18, 2025
By Andrew J. Hull A recent DEA decision revoking the registration of a Louisiana pharmacy sheds light on the Agencys approach to crediting one experts testimony over that of another expert during an administrative hearing. The discussion of the Agencys expectations of the form and substance of expert witness testimony is a must-read for entities or individuals facing a DEA order to show cause hearing.
STAT
FEBRUARY 18, 2025
XRHealth is on a shopping spree, buying three companies in as many years, as it aims to build a leading platform for therapeutic virtual reality. The latest: It’s acquiring RealizedCare, a company that couples immersive experiences with coaches for chronic pain management. XRHealth and RealizedCare own assets for a range of virtual reality headset-based experiences designed to help treat mental health, chronic pain, and other conditions.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
FEBRUARY 18, 2025
Y ou’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Bill, baby, bill: Abridge announces $250 million raise Abridge announced a $250 million Series D fundraise co-led by investor Elad Gil and IVP with participation from many other notable venture firms.
Drug Topics
FEBRUARY 18, 2025
Patients with musculoskeletal pain were treated with cryotherapy spray to assess its use in providing immediate and sustained pain relief.
PharmaVoice
FEBRUARY 18, 2025
Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.
Drug Topics
FEBRUARY 18, 2025
Explore key legislative actions changing pharmacy practice in 2025 and beyond.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
FEBRUARY 18, 2025
Research suggests H5N1 may be spreading undetected among humans, particularly in veterinarians with frequent animal exposure.
Drug Topics
FEBRUARY 18, 2025
The FDA initially approved deucravacitinib (Sotyktu) in September 2022 to treat moderate-to-severe plaque psoriasis.
Pharmacy Times
FEBRUARY 18, 2025
New data from the longest known trial of pediatrics and adolescents in the postacute phase of COVID-19 show they are at a heightened risk of gastrointestinal tract symptoms.
Drug Topics
FEBRUARY 18, 2025
Previously, dupilumab (Dupixent) received orphan drug designation for bullous pemphigoid.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Healthcare
FEBRUARY 18, 2025
At ViVE 2025, digital health leaders reveal new generative AI products and industry cost savings reports. Here's a look at some quick hits from the show floor.
STAT
FEBRUARY 18, 2025
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning, we’ve got a lot to go over. As one editor put it on Friday: “‘When it rains it pours’ doesn’t seem to adequately capture the deluge of news.
Pharmaceutical Technology
FEBRUARY 18, 2025
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues.
Fierce Healthcare
FEBRUARY 18, 2025
The quarterly numbers are a dip from the year prior and come shortly after news of mass layoffs among nonclinical employees. Alongside more than $200 million of expected savings per year, management said the cuts would "improve efficiency" and "empower staff.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
FEBRUARY 18, 2025
The FDA is scheduled to deliver a verdict on Sanofi and Regeneron's Dupixent for rare autoimmune skin disorder bullous pemphigoid in June
Fierce Healthcare
FEBRUARY 18, 2025
The order directs the Domestic Policy Council to make policy recommendations to protect IVF access and aggressively reduce the associated costs for treatment.
Pharmacy Times
FEBRUARY 18, 2025
Clinical decision support systems based on algorithms have improved outcomes and reduced costs in other health care settings.
pharmaphorum
FEBRUARY 18, 2025
ALS candidates from Biohaven, Prilenia, Clene, and UCB were unable to slow disease progression in the study, but two showed signs of efficacy
Pharmacy Times
FEBRUARY 18, 2025
Although larsucosterol did not show statistical significance, it showed clinically meaningful trends in 90-day mortality in patients with severe alcohol-associated hepatitis.
pharmaphorum
FEBRUARY 18, 2025
Sanofi has claimed FDA approval for the first biosimilar of Novo Nordisk's rapid-acting insulin analogue Novolog
Pharmacy Times
FEBRUARY 18, 2025
Prescribing and dosing appropriate treatments for patients with sickle cell disease while managing episodes of acute pain are some of the integral roles of pharmacists.
Fierce Healthcare
FEBRUARY 18, 2025
Executives at Risant Health and Geisinger Health offered a look under the hood during a fireside chat at ViVE 2025 and shared details about the value-based "engine" that drives its work.
Pharmaceutical Technology
FEBRUARY 18, 2025
The FDA has accepted Gileads new drug application with a decision expected by 19 June 2025.
Pharmaceutical Commerce
FEBRUARY 18, 2025
In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of sales, life sciences, Loftware, comments on why she believes supply chain collaboration is becoming increasingly critical today.
STAT
FEBRUARY 18, 2025
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today we take a closer look at what firings at U.S. health agencies mean for the country’s broader scientific enterprise. Also, a hearty congrats to my coworkers Bob Herman, Tara Bannow, Casey Ross, and Lizzy Lawrence, who won a Polk award — STAT’s third — for their coverage of UnitedHealth Group.
pharmaphorum
FEBRUARY 18, 2025
Shionogi will market the EndeavorRide app, originally licensed from Akili, in Japan following its approval by the MHLW regulator
Pharmaceutical Technology
FEBRUARY 18, 2025
The US FDA has granted fast track designation to Rznomics' RZ-001 for the treatment of hepatocellular carcinoma (HCC).
Pharmacy Times
FEBRUARY 18, 2025
Second-line and later treatment options for small cell lung cancer are limited.
Pharmaceutical Technology
FEBRUARY 18, 2025
HMRI has signed a memorandum of understanding (MoU) with Novartis Australia for expediting medical research to drive healthcare projects.
Expert insights. Personalized for you.
Let's personalize your content